O-304 (ATX-304): Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 4 sources cited

Overview

O-304 is a novel small-molecule AMPK activator developed by Betagenon AB that directly activates AMPK by preventing its dephosphorylation. Unlike indirect AMPK activators, O-304 maintains AMPK in its active phosphorylated state, producing exercise-mimetic and glucose-lowering effects. It has completed Phase IIa clinical trials for type 2 diabetes with promising results.

Mechanism of Action

O-304 activates AMPK through a different route: it suppresses the dephosphorylation of already phosphorylated AMPK rather than mimicking AMP, although how it does so is not established. This preserves physiological AMPK regulation while amplifying the signal. The downstream effects include increased glucose uptake in skeletal muscle via GLUT4 translocation, enhanced fatty acid oxidation, reduced hepatic glucose output, and stimulation of mitochondrial biogenesis. O-304 also improved peripheral microvascular perfusion and lowered blood pressure in both animals and trial participants, an effect not reported for other AMPK activators in clinical testing.

O-304 (ATX-304) Benefits: What the Research Shows

  • Steneberg et al. (2018) in JCI Insight reported that in the 28-day TELLUS phase IIa trial in 65 type 2 diabetes patients on metformin, fasting plasma glucose fell by 0.60 mmol/L on O-304 against 0.10 mmol/L on placebo in the analysis of patients starting above 7 mmol/L, along with a reduction in HOMA-IR
  • The same trial measured microvascular perfusion in calf muscle by MRI and also found reduced blood pressure; laser Doppler imaging was the method used in the mouse experiments
  • Preclinical studies showed O-304 averted the rise in fasting glucose and insulin and prevented insulin resistance in diet-induced obese mice, without reducing body weight
  • Research demonstrated O-304's unique mechanism of preventing AMPK dephosphorylation rather than mimicking AMP
  • Animal studies showed increased cardiac glucose uptake and improved left ventricular stroke volume with no increase in heart weight and no cardiac hypertrophy, and improved cardiac function in aged mice

O-304 (ATX-304) Dosage

  • Phase IIa clinical trial dose: 1,000 mg per day orally, given as a suspension
  • No established off-label or research community protocol exists
  • The phase IIa trial lasted 28 days; the authors noted that plasma steady state is not reached until about day 14, so 28 days may have been too short to show the full glucose-lowering effect
  • Oral bioavailability allows simple administration without injection
  • Being studied as a potential oral exercise mimetic and diabetes treatment
  • Not widely available outside clinical research settings
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

O-304 (ATX-304) Side Effects & Safety

Known Side Effects

  • Gastrointestinal discomfort such as mild nausea or diarrhea, though the published trial report states only that O-304 was well tolerated and does not list adverse events by type
  • Hypoglycemia risk — particularly when combined with insulin or sulfonylureas
  • Headache, which is likewise not broken out in the published trial report
  • Limited side effect data due to early-stage clinical development

Safety Profile

O-304 was reported to be well tolerated in its 28-day Phase IIa trial, with no ECG abnormalities and no effect on left ventricular mass, and a later paper describes it as well tolerated in humans. The published report does not list which adverse events were most common. As an AMPK activator, the theoretical risk of hypoglycemia exists when combined with other glucose-lowering agents. Long-term safety data is not yet available. The compound is still in clinical development and not approved for any indication. Access is limited to clinical trial settings and select research suppliers.

What to Expect

Week 1: Subtle improvements in blood glucose stability may be measurable. No dramatic subjective effects expected. Week 2–3: Fasting glucose levels trend downward. Some users may notice improved exercise endurance or recovery. Week 4+: Clinical trial data showed significant glucose-lowering and microvascular improvements at this timeframe. Body composition changes may begin to emerge with consistent use. As an early-stage compound, user experience data is very limited compared to established peptides.

Common Stacks

Storage & Handling

Store O-304 tablets or capsules at room temperature (15–25°C) in a dry place away from light and moisture. As an oral small molecule, it is relatively stable compared to injectable peptides. Follow manufacturer guidelines for specific product formulations.

Pricing & Available Variants

$200price range
100mg x 60 Capsules

Prices sourced from peptides.gg marketplace. Prices may vary.

References

Related Peptides

Track O-304 (ATX-304) in Your Protocol

Log your O-304 (ATX-304) doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free